Precision cancer diagnostics specialist Epredia, a subsidiary of PHC Holdings Corporation (TSE:6523), and Mindpeak, a provider of AI solutions for clinical and research pathology, on Tuesday announced a distribution agreement to supply Mindpeak's AI-based image recognition modules to Epredia's digital pathology customers in the European Union.
The software provides pixel-level analysis of digital tissue images to support objective, reproducible assessments across breast, lung, and gastrointestinal cancers, biomarker quantification, and research applications, while operating without cloud connectivity to maintain data privacy. Mindpeak's portfolio includes both CE-marked and research-use-only modules.
Epredia will offer the AI tools for clinical diagnostics, translational research, and pharmaceutical development and plans to explore integration into its E1000 Dx Digital Pathology Solution workflow to enable streamlined data exchange and high-throughput image review of up to 1,500 slides daily.
This agreement expands Epredia's end-to-end pathology portfolio spanning consumables, instruments, and advanced image management systems with AI-enabled capabilities.
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Akeso publishes ivonescimab Phase II study results in Nature Medicine
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101